| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Unknown |
| Molecule Category: | UNKNOWN |
| UNII: | VVA2ZDV3LX |
Physicochemical Descriptors
| Property Name | Value |
|---|---|
| Molecular Formula | C28H27Cl2N3O4 |
| Molecular Weight | 540.45 |
| AlogP | 6.9 |
| Hydrogen Bond Acceptor | 6.0 |
| Hydrogen Bond Donor | 1.0 |
| Number of Rotational Bond | 7.0 |
| Polar Surface Area | 80.73 |
| Molecular species | None |
| Aromatic Rings | 4.0 |
| Heavy Atoms | 37.0 |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| AGONIST | Bile acid receptor FXR agonist |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Enzyme
Hydrolase
|
- | - | - | - | 0.5315 | |
|
Enzyme
Oxidoreductase
|
- | - | - | - | 25 | |
|
Enzyme
|
- | - | - | - | 0.5315 | |
|
Membrane receptor
Family A G protein-coupled receptor
Small molecule receptor (family A GPCR)
Lipid-like ligand receptor (family A GPCR)
Steroid-like ligand receptor
|
1497 | - | - | - | - | |
|
Transcription factor
Nuclear receptor
Nuclear hormone receptor subfamily 1
Nuclear hormone receptor subfamily 1 group H
Nuclear hormone receptor subfamily 1 group H member 4
|
4-238 | - | - | - | - |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Non-alcoholic Fatty Liver Disease | 2 | D065626 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL4594506 |
| FDA SRS | VVA2ZDV3LX |
| PubChem | 25204767 |
CONTENTS